GlassScriptPhysician profile
Milton W Seiler
NPI 1386609147
$1,375.11
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $629 · 2022: $508 · 2024: $19.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $134.11 | 2019-2022 | |
| Janssen Biotech, INC. | $131.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $126.56 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $79.11 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $71.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $66.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $66.02 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $54.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.83 | 2021 | |
| Astellas Pharma US INC | $49.14 | 2021 | |
| Seagen INC. | $28.21 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $26.39 | 2022 | |
| Acrotech Biopharma INC. | $25.28 | 2021 | |
| Emmaus Medical, INC. | $24.14 | 2021 | |
| Adc Therapeutics America, INC. | $22.85 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acceleron Pharma, INC. | $22.74 | 2021 | |
| Eisai INC. | $20.47 | 2022 | |
| G1 Therapeutics, INC. | $19.99 | 2022 | |
| Blueprint Medicines Corporation | $19.91 | 2022 | |
| Tempus Ai, INC | $19.90 | 2024 | |
| Progenics Pharmaceuticals, INC. | $19.55 | 2022 | |
| Sobi, INC | $19.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.26 | 2022 | |
| Lilly USA, LLC | $19.06 | 2022 | |
| Incyte Corporation | $18.76 | 2021 | |
| Celgene Corporation | $18.52 | 2022 | |
| Beigene USA, INC. | $18.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.94 | 2022 | |
| Amgen INC. | $17.91 | 2021 | |
| Rigel Pharmaceuticals, INC. | $17.73 | 2021 | |
| Servier Pharmaceuticals LLC | $16.75 | 2022 | |
| Tg Therapeutics, INC. | $16.02 | 2021 | |
| Coherus Oncology, INC. | $15.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.46 | 2019 | |
| Morphosys, US INC. | $14.69 | 2021 | |
| Exelixis INC. | $13.84 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.95 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Taiho Oncology, INC. | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Seiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.